410 related articles for article (PubMed ID: 33424836)
21. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
Marijt KA; Doorduijn EM; van Hall T
Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
[TBL] [Abstract][Full Text] [Related]
22. Antigen discovery for the development of cancer immunotherapy.
Ahn R; Cui Y; White FM
Semin Immunol; 2023 Mar; 66():101733. PubMed ID: 36841147
[TBL] [Abstract][Full Text] [Related]
23. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
24. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
25. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
26. Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.
Aparicio B; Theunissen P; Hervas-Stubbs S; Fortes P; Sarobe P
Hum Vaccin Immunother; 2024 Dec; 20(1):2303799. PubMed ID: 38346926
[TBL] [Abstract][Full Text] [Related]
27. Computational Prediction and Validation of Tumor-Associated Neoantigens.
Roudko V; Greenbaum B; Bhardwaj N
Front Immunol; 2020; 11():27. PubMed ID: 32117226
[TBL] [Abstract][Full Text] [Related]
28. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
29. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer.
Benvenuto M; Focaccetti C; Izzi V; Masuelli L; Modesti A; Bei R
Semin Cancer Biol; 2021 Jul; 72():65-75. PubMed ID: 31698088
[TBL] [Abstract][Full Text] [Related]
30. Improving Cancer Immunotherapies through Empirical Neoantigen Selection.
Nogueira C; Kaufmann JK; Lam H; Flechtner JB
Trends Cancer; 2018 Feb; 4(2):97-100. PubMed ID: 29458967
[TBL] [Abstract][Full Text] [Related]
31. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V; Rosenberg SA
Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
[TBL] [Abstract][Full Text] [Related]
32. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
[TBL] [Abstract][Full Text] [Related]
33. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
34. Targeting Neoantigens for Personalised Immunotherapy.
Pritchard AL
BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
[TBL] [Abstract][Full Text] [Related]
35. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J; Xiao Z; Wang D; Jia L; Nie S; Zeng X; Hu W
Mol Cancer; 2023 Aug; 22(1):141. PubMed ID: 37649123
[TBL] [Abstract][Full Text] [Related]
36. Determinants for Neoantigen Identification.
Garcia-Garijo A; Fajardo CA; Gros A
Front Immunol; 2019; 10():1392. PubMed ID: 31293573
[TBL] [Abstract][Full Text] [Related]
37. [Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations].
Sasada T
Nihon Rinsho; 2017 Feb; 75(2):189-195. PubMed ID: 30562851
[TBL] [Abstract][Full Text] [Related]
38. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
Zhao W; Wu J; Chen S; Zhou Z
Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic cancer/testis antigens: prime candidates for immunotherapy.
Gjerstorff MF; Andersen MH; Ditzel HJ
Oncotarget; 2015 Jun; 6(18):15772-87. PubMed ID: 26158218
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment antigens.
Andersen MH
Semin Immunopathol; 2023 Mar; 45(2):253-264. PubMed ID: 36175673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
